Wieland Capital

Cycuria Therapeutics is a biotechnology company focused on developing innovative protein-based therapies for treating blood cancers, with a particular emphasis on acute myeloid leukemia (AML). The company's approach involves creating engineered proteins that selectively target and eliminate leukemic stem cells and AML blasts, while preserving healthy blood cells. This targeted strategy aims to reduce treatment-related toxicity, stimulate the immune system, and improve overall patient outcomes for AML and other challenging cancer types.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.

Lifespin is a data company specializing in mapping human health conditions. It provides a highly scalable method to digitize metabolomes on a population level, defining the baseline for human health and enabling early detection and monitoring of diseases through digital products for providers and patients.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.